Harrow (NASDAQ:HROW) Raised to Hold at Wall Street Zen

Harrow (NASDAQ:HROW) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

Other equities research analysts also recently issued research reports about the company. BTIG Research reissued a “buy” rating and issued a $63.00 price objective on shares of Harrow in a report on Tuesday, August 11th. Zacks Research lowered shares of Harrow from a “hold” rating to a “strong sell” rating in a research report on Tuesday, August 11th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Harrow in a research report on Monday, July 20th. Finally, Cantor Fitzgerald cut their price target on shares of Harrow from $91.00 to $88.00 and set an “overweight” rating for the company in a research note on Wednesday, May 13th. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Harrow currently has an average rating of “Moderate Buy” and an average price target of $69.43.

Harrow Price Performance

Shares of HROW stock opened at $40.03 on Friday. The company has a current ratio of 2.24, a quick ratio of 2.08 and a debt-to-equity ratio of 19.70. Harrow has a 1 year low of $28.54 and a 1 year high of $54.85. The firm’s fifty day moving average price is $40.94 and its two-hundred day moving average price is $39.86. The firm has a market capitalization of $1.50 billion, a P/E ratio of -40.03 and a beta of 0.28.

Harrow (NASDAQ:HROW) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.28). The company had revenue of $70.66 million during the quarter, compared to the consensus estimate of $70.35 million. Harrow had a negative net margin of 13.51% and a negative return on equity of 38.00%. On average, equities analysts predict that Harrow will post 0.11 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. bought a new stake in Harrow in the 2nd quarter valued at $116,373,000. Vanguard Group Inc. boosted its position in Harrow by 2.7% during the fourth quarter. Vanguard Group Inc. now owns 1,921,683 shares of the company’s stock worth $94,162,000 after purchasing an additional 50,889 shares during the period. Luxor Capital Group LP boosted its position in Harrow by 22.0% during the first quarter. Luxor Capital Group LP now owns 1,119,400 shares of the company’s stock worth $39,470,000 after purchasing an additional 201,859 shares during the period. Geode Capital Management LLC increased its holdings in shares of Harrow by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 785,089 shares of the company’s stock valued at $38,477,000 after purchasing an additional 9,445 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Harrow by 56.4% in the first quarter. Dimensional Fund Advisors LP now owns 579,520 shares of the company’s stock valued at $20,428,000 after purchasing an additional 208,972 shares during the last quarter. 72.76% of the stock is currently owned by institutional investors.

Key Headlines Impacting Harrow

Here are the key news stories impacting Harrow this week:

• Positive Sentiment: Harrow’s potential acquisition or commercialization of Viatris’ Tyrvaya could create a new growth opportunity if the company can expand the ophthalmic drug’s sales and reach. Viatris Is Selling Tyrvaya, but Could Harrow Turn It Into a Growth Engine?
• Positive Sentiment: A Seeking Alpha analysis characterized Harrow’s second-quarter turnaround as sufficient to support a cautious-buy view, offering a more constructive perspective on the company’s operating trajectory. Harrow: The Q2 Turnaround Is Enough for a Cautious Buy
• Positive Sentiment: BTIG Research reaffirmed its buy rating, signaling continued confidence in Harrow’s longer-term prospects. BTIG Research Reaffirms Buy Rating for Harrow
• Neutral Sentiment: HC Wainwright made a minor increase to its Q4 2027 EPS forecast, to $1.07 from $1.06, indicating limited improvement in one later-period estimate.
• Negative Sentiment: HC Wainwright significantly reduced its earnings forecasts: FY2026 moved to a loss of $0.57 per share from earnings of $0.15, FY2027 fell to $0.88 from $1.14, and Q3 2026 declined to $0.01 from $0.26. Estimates for Q1 and Q2 2027 were also lowered to losses of $0.63 and $0.12 per share, respectively. The revisions contrast with the current full-year consensus estimate of $0.30.
• Negative Sentiment: Zacks Research downgraded Harrow from “hold” to “strong sell,” adding to concerns about valuation and near-term profitability. Zacks.com
• Negative Sentiment: Recent coverage linked a prior gap lower in HROW shares to weak earnings, reinforcing investor concerns about the company’s ongoing losses and execution. Harrow Shares Gap Down Following Weak Earnings

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.